Discovery of neutralizing anti-IL-5 nanobodies and epitope-guided engineering of a biparatopic anti-IL-5 nanobody

Journal of Chemical Sciences · Springer Nature · 2026-09-17 · DOI: 10.1007/s12257-026-00330-1

Аннотация

Interleukin-5 (IL-5) is a key regulator of eosinophil-mediated inflammation and a validated therapeutic target for severe eosinophilic asthma. Although monoclonal antibodies targeting IL-5 have demonstrated clinical efficacy, their application is limited by high production costs and suboptimal tissue penetration. Nanobodies (VHHs), owing to their small size and favorable biophysical properties, represent a promising alternative therapeutic format. In this study, we employed a combinatorial phage display strategy integrating solid-phase and liquid-phase panning to isolate IL-5-specific nanobodies from an alpaca immune library. Subsequent screening, sequencing, recombinant expression, and functional characterization identified several candidate VHHs with IL-5 binding and blocking activity. Among them, AIL-C14-Fc, AIL-C506-Fc, and AIL-C633-Fc exhibited sub-nanomolar affinity and effectively inhibited the interaction between IL-5 and IL-5Rα. Epitope binning showed that AIL-C14 and AIL-C506 competed with hu39D10, whereas AIL-C633 recognized a distinct epitope region. Guided by the epitope-binning results, biparatopic VHH constructs were rationally designed. Notably, C14-(G4S)₄-C633-His showed the strongest inhibitory activity among the tested biparatopic nanobodies in the TF-1 cell proliferation assay, with an IC₅₀ value 41.9% lower than that of hu39D10, although its potency was comparable to that of the monospecific bivalent C633-(G4S)₄-C633-His construct. C14-(G4S)₄-C633-His also exhibited high monomer content and good thermal stability. Competitive binding assays and AlphaFold3-based modeling supported the retention of dual-epitope recognition in the biparatopic format. These findings provide a basis for epitope-guided engineering of anti-IL-5 biparatopic VHHs and support further evaluation of C14-(G4S)₄-C633-His as an IL-5-blocking candidate.

Читать у издателя →

Похожие статьи